Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week.
Publication
, Journal Article
Fiuzat, M; Hamo, CE; Butler, J; Abraham, WT; DeFilippis, EM; Fonarow, GC; Lindenfeld, J; Mentz, RJ; Psotka, MA; Solomon, SD; Teerlink, JR ...
Published in: J Am Coll Cardiol
February 8, 2022
With the current landscape of approved therapies for heart failure (HF), there is a need to determine the role of a standard background therapy against which novel therapies are studied. The Heart Failure Collaboratory convened a multistakeholder group of clinical investigators, clinicians, patients, government representatives including U.S. Food and Drug Administration and National Institutes of Health participants, payers, and industry in March 2021 to discuss whether standardization of background drug therapy is necessary in clinical trials in patients with HF. The current paper summarizes the discussion and provides potential conceptual approaches, with a focus on therapies indicated for HF with reduced ejection fraction.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Am Coll Cardiol
DOI
EISSN
1558-3597
Publication Date
February 8, 2022
Volume
79
Issue
5
Start / End Page
504 / 510
Location
United States
Related Subject Headings
- Stroke Volume
- Periodicals as Topic
- Humans
- Heart Failure
- Clinical Trials as Topic
- Cardiovascular System & Hematology
- Cardiovascular Agents
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Fiuzat, M., Hamo, C. E., Butler, J., Abraham, W. T., DeFilippis, E. M., Fonarow, G. C., … O’Connor, C. M. (2022). Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week. J Am Coll Cardiol, 79(5), 504–510. https://doi.org/10.1016/j.jacc.2021.11.033
Fiuzat, Mona, Carine E. Hamo, Javed Butler, William T. Abraham, Ersilia M. DeFilippis, Gregg C. Fonarow, Joann Lindenfeld, et al. “Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week.” J Am Coll Cardiol 79, no. 5 (February 8, 2022): 504–10. https://doi.org/10.1016/j.jacc.2021.11.033.
Fiuzat M, Hamo CE, Butler J, Abraham WT, DeFilippis EM, Fonarow GC, et al. Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week. J Am Coll Cardiol. 2022 Feb 8;79(5):504–10.
Fiuzat, Mona, et al. “Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week.” J Am Coll Cardiol, vol. 79, no. 5, Feb. 2022, pp. 504–10. Pubmed, doi:10.1016/j.jacc.2021.11.033.
Fiuzat M, Hamo CE, Butler J, Abraham WT, DeFilippis EM, Fonarow GC, Lindenfeld J, Mentz RJ, Psotka MA, Solomon SD, Teerlink JR, Vaduganathan M, Vardeny O, McMurray JJV, O’Connor CM. Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week. J Am Coll Cardiol. 2022 Feb 8;79(5):504–510.
Published In
J Am Coll Cardiol
DOI
EISSN
1558-3597
Publication Date
February 8, 2022
Volume
79
Issue
5
Start / End Page
504 / 510
Location
United States
Related Subject Headings
- Stroke Volume
- Periodicals as Topic
- Humans
- Heart Failure
- Clinical Trials as Topic
- Cardiovascular System & Hematology
- Cardiovascular Agents
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology